| Quarter | Holdings | Value, Excl. Options ($000) | Top Holdings | Form Type | Date Filed | Filing ID |
|---|---|---|---|---|---|---|
| Q3 2026 | 36 | 2,034,164 | ZYME, ANAB, BMY calls, CGON | 13F-HR | 11/16/2026 | 000093583626000577 |
| Q2 2026 | 33 | 2,016,754 | ZYME, ANAB, AKTS, CGON | 13F-HR | 8/14/2026 | 000093583626000415 |
| Q1 2026 | 30 | 2,340,002 | ZYME, ANAB, JAZZ, CNTA | 13F-HR | 5/15/2026 | 000093583626000270 |
| Q4 2025 | 30 | 2,190,818 | ZYME, ANAB, JAZZ, CRNX | 13F-HR | 2/17/2026 | 000093583626000101 |
| Q3 2025 | 30 | 2,083,869 | ZYME, ANAB, QURE, JAZZ | 13F-HR | 11/14/2025 | 000093583625000671 |
| Q2 2025 | 37 | 1,687,449 | ZYME, APLS, JAZZ, ANAB | 13F-HR | 8/14/2025 | 000093583625000506 |
| Q1 2025 | 46 | 1,683,936 | APLS, JAZZ, ZYME, ANAB | 13F-HR | 5/15/2025 | 000093583625000338 |
| Q4 2024 | 59 | 2,503,454 | APLS, ZYME, CRNX, JAZZ | 13F-HR | 2/14/2025 | 000093583625000164 |
| Q3 2024 | 64 | 2,920,208 | APLS, ANAB, CRNX, PRTA | 13F-HR | 11/14/2024 | 000093583624000682 |
| Q2 2024 | 55 | 3,268,882 | APLS, PRTA, SRPT, ANAB | 13F-HR | 8/14/2024 | 000093583624000519 |
| Q1 2024 | 59 | 3,938,511 | APLS, PRTA, ARVN, SRPT | 13F-HR | 5/15/2024 | 000093583624000391 |
| Q4 2023 | 51 | 3,851,538 | APLS, MRTX, PRTA, ARVN | 13F-HR | 2/14/2024 | 000093583624000163 |
| Q3 2023 | 51 | 2,935,965 | PRTA, APLS, MRTX, LKFT | 13F-HR | 11/14/2023 | 000093583623000696 |
| Q2 2023 | 53 | 3,794,817 | PRTA, APLS, SRPT, JNJ calls | 13F-HR | 8/14/2023 | 000093583623000570 |
| Q1 2023 | 58 | 3,105,402 | PRTA, SRPT, APLS, LKFT | 13F-HR | 5/15/2023 | 000093583623000412 |
| Q4 2022 | 66 | 3,285,597 | PRTA, SRPT, APLS, ANAB | 13F-HR | 2/14/2023 | 000093583623000229 |
| Q3 2022 | 76 | 3,387,071 | PRTA, APLS, SRPT, ANAB | 13F-HR | 11/14/2022 | 000156761922019766 |
| Q2 2022 | 80 | 2,878,118 | PRTA, APLS, SRPT, SGEN | 13F-HR | 8/15/2022 | 000156761922016025 |
| Q1 2022 | 87 | 3,196,181 | PRTA, APLS, LKFT, ANAB | 13F-HR | 5/16/2022 | 000156761922010677 |
| Q4 2021 | 76 | 3,134,114 | PRTA, ANAB, RCUS, XNCR | 13F-HR | 2/14/2022 | 000156761922003866 |
| Q3 2021 | 71 | 2,843,542 | PRTA, MORF, ANAB, RCUS | RESTATEMENT | 11/22/2021 | 000156761921020941 |
| Q2 2021 | 72 | 2,675,754 | PRTA, MORF, ANAB, XNCR | 13F-HR | 8/16/2021 | 000156761921015658 |
| Q1 2021 | 71 | 2,248,383 | PRTA, XNCR, MORF, ANAB | 13F-HR | 5/17/2021 | 000156761921010348 |
| Q4 2020 | 66 | 1,797,231 | XNCR, RLAY, STTK, SPRY | 13F-HR | 2/16/2021 | 000156761921003800 |
| Q3 2020 | 50 | 1,385,947 | XNCR, KURA, RLAY, PRTA | 13F-HR | 11/16/2020 | 000156761920019716 |
| Q2 2020 | 49 | 1,335,693 | XNCR, PRTA, ORIC, MORF | 13F-HR | 8/14/2020 | 000156761920015276 |
| Q1 2020 | 51 | 957,232 | PRTA, XNCR, ARVN, DRNA | 13F-HR | 5/15/2020 | 000156761920010491 |
| Q4 2019 | 44 | 1,054,034 | PRTA, XNCR, DRNA, FGEN | RESTATEMENT | 2/18/2020 | 000156761920004215 |
| Q3 2019 | 38 | 749,426 | XNCR, PRTA, ONCE, KURA | 13F-HR | 11/14/2019 | 000156761919021573 |
| Q2 2019 | 39 | 970,382 | KURA, XNCR, ARGX, CRSP | 13F-HR | 8/14/2019 | 000156761919017041 |
| Q1 2019 | 41 | 923,849 | ARGX, KURA, MRTX, CRSP | 13F-HR | 5/15/2019 | 000156761919011227 |
| Q4 2018 | 53 | 869,349 | ARGX, KURA, FGEN, IRWD | 13F-HR | 2/14/2019 | 000156761919004400 |
| Q3 2018 | 50 | 966,248 | FGEN, ASMB, IRWD, ASND | 13F-HR | 11/14/2018 | 000156761918006356 |
| Q2 2018 | 33 | 914,687 | FGEN, IRWD, ASMB, ASND | 13F-HR | 8/14/2018 | 000156761918000858 |
| Q1 2018 | 31 | 933,286 | ASMB, ASND, FGEN, IRWD | 13F-HR | 5/15/2018 | 000114036118023901 |
| Q4 2017 | 30 | 745,714 | ASMB, FGEN, CELGENE CORPORATION calls, IRWD | 13F-HR | 2/14/2018 | 000114036118007942 |
| Q3 2017 | 39 | 730,261 | ASMB, FGEN, IRWD, ASND | 13F-HR | 11/14/2017 | 000114036117042799 |
| Q2 2017 | 36 | 433,545 | ALEXION PHARMACEUTICALS, INC calls, IRWD, ASMB, FGEN | 13F-HR | 8/14/2017 | 000114036117032004 |
| Q1 2017 | 33 | 361,177 | ASMB, IRWD, LKFT, GILEAD SCIENCES INC calls | RESTATEMENT | 5/19/2017 | 000114036117021481 |
| Q4 2016 | 30 | 288,479 | IRWD, LKFT, ASMB, ALXN | RESTATEMENT | 2/15/2017 | 000114036117007745 |
| Q4 2016 | 1 | 14,684 | FGEN | NEW HOLDINGS | 2/15/2017 | 000114036117007752 |
| Q3 2016 | 31 | 261,623 | IRWD, LKFT, BRISTOL MYERS SQUIBB CO calls, ASMB | 13F-HR | 11/14/2016 | 000114036116086430 |
| Q2 2016 | 32 | 219,175 | IRWD, LKFT, RTRX, CYTK | 13F-HR | 8/15/2016 | 000114036116076455 |
| Q1 2016 | 37 | 247,864 | IRWD, FPRX, EPZM, FGEN | 13F-HR | 5/16/2016 | 000114036116065705 |
| Q4 2015 | 31 | 270,004 | FGEN, FPRX, JAZZ PHARMACEUTICALS calls, RTRX | 13F-HR | 2/16/2016 | 000114036116052684 |
| Q3 2015 | 25 | 216,168 | FGEN, ATRA, ARRAY BIOPHARMA INC, RTRX | 13F-HR | 11/16/2015 | 000114036115041435 |
| Q2 2015 | 25 | 283,588 | ATRA, EPZM, ASMB, FGEN | 13F-HR | 8/14/2015 | 000114036115031882 |
| Q1 2015 | 23 | 267,814 | ATRA, EPZM, RCPT, ARRAY BIOPHARMA SR CONV NT 3.000% Due 06/01/2020 | RESTATEMENT | 5/18/2015 | 000114036115020512 |
| Q4 2014 | 22 | 186,637 | KITE, CLVSQ, RCPT, ARRAY BIOPHARMA INC | 13F-HR | 2/17/2015 | 000092189515000435 |
Each security where the latest filing since 12/18/2024 is a 13D, newest first.
| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
|
Aktis Oncology, Inc.
13D
AKTS · 01021M104
|
9.1% |
1/20/2026
Event 1/12/2026
|
||||
| EcoR1 Capital, LLC | 9.1% | |||||
| Oleg Nodelman | 9.1% | |||||
| EcoR1 Capital Fund Qualified, L.P. | 8.2% | |||||
|
Zymeworks Inc.
13D/A
ZYME · 98985Y108
|
30.7% |
11/19/2025
Event 11/16/2025
|
||||
| EcoR1 Capital, LLC | 30.7% | |||||
| Oleg Nodelman | 30.7% | |||||
| EcoR1 Capital Fund Qualified, L.P. | 28.8% | |||||
|
Galapagos NV
13D/A
LKFT · 36315X101
|
13.2% |
7/28/2025
Event 7/24/2025
|
||||
| EcoR1 Capital, LLC | 13.2% | |||||
| Oleg Nodelman | 13.2% | |||||
| EcoR1 Capital Fund Qualified, L.P. | 12.4% | |||||
| EcoR1 Capital Fund, L.P. | 0.8% | |||||
|
iTeos Therapeutics, Inc.
13D
ITOS · 46565G104
|
27.9% |
5/16/2025
Event 5/15/2025
|
||||
| EcoR1 Capital, LLC | 27.9% | |||||
| Oleg Nodelman | 27.9% | |||||
| EcoR1 Capital Fund Qualified, L.P. | 26.2% | |||||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (1) | ||||||
|
Prothena Corp Public Ltd Co
13D/A
PRTA · G72800108
|
0% |
5/29/2025
Event 5/27/2025
|
||||
| EcoR1 Capital, LLC | 0% | |||||
| Oleg Nodelman | 0% | |||||
| EcoR1 Capital Fund Qualified, L.P. | 0% | |||||
30 other securities where the latest filing is a 13G, the newest filed 11/16/2026. View all